Isolere Bio Team Awarded Grant for Innovative, Low-Cost Monoclonal Antibody (mAb) Manufacturing
Durham, NC (Dec 10, 2025) – Isolere Bio is proud to announce that it has been awarded a grant for utilizing IsoTag™ reagent technology for the development of low-cost monoclonal antibody (mAb) production as a part of a Grand Challenge initiative from the Gates Foundation. The Isolere Bio team submitted a proposal entitled, “Exceptionally Low-Cost Downstream Processing Using Column-Less Purification Technology,” as a part of this low-cost monoclonal antibody production initiative. As stated in a press release from the foundation:
Isolere Bio, a Donaldson Life Sciences business, in the U.S. will develop a biomanufacturing platform for low-cost production of monoclonal antibodies based on a multidomain synthetic protein enabling both capture and purification of the antibody in a chromatography-free process. The synthetic protein includes an antibody-binding affinity tag, and it enables liquid-liquid phase separation and selective concentration of the bound antibody. Key steps in the biomanufacturing process will be targeted to decrease costs and improve performance. This includes high-throughput experiments to identify conditions that improve the recycling of the synthetic protein, as well as tests to optimize the removal of viral contaminants during the purification process. Subsequently, larger-scale production will be piloted to identify the critical parameters required to scale up the platform.
Read the full press release here: Grand Challenges Announces Awards for "Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing"
Michael Dzuricky
"We are thrilled to receive new support for our technology that aims to enable greater access to antibody therapies by dramatically reducing costs. Our goals for the IsoTag™ reagent technology are moonshot worthy with outsized potential impact on the field."
- Michael Dzuricky, PhD, Director, Advanced R&D, Isolere Bio